SK biopharmaceuticals Co., Ltd. Logo

SK biopharmaceuticals Co., Ltd.

Develops and commercializes CNS and oncology therapies for global markets, focusing on the U.S.

326030 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교역로 221, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SK Biopharmaceuticals is a global, fully integrated pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies. The company's primary therapeutic area is central nervous system (CNS) disorders, with an expanding pipeline in oncology. Its business model encompasses the entire value chain, from research and development to direct commercialization in key global markets, particularly the United States. The company's flagship product is cenobamate (marketed as XCOPRI® in the U.S.), an anti-seizure medication that has demonstrated significant commercial growth. SK Biopharmaceuticals actively incorporates advanced technologies, including artificial intelligence, to accelerate its drug development process and address unmet medical needs.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for SK biopharmaceuticals Co., Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-16 00:00
Regulatory News Service
투자판단관련주요경영사항
Korean 12.8 KB
2025-08-29 00:00
Regulatory News Service
대규모기업집단현황공시[분기별공시(개별회사용)]
Korean 5.9 KB
2025-08-14 00:00
Environmental & Social Information
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Korean 2.2 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 4.6 MB
2025-08-05 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 15.7 KB
2025-07-30 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.0 KB
2025-07-29 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 8.3 KB

Automate Your Workflow. Get a real-time feed of all SK biopharmaceuticals Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SK biopharmaceuticals Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway SOFTX
Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan 4597
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden SPAGO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden SPRINT
STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany SAZ
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea 052020
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan 4888

Talk to a Data Expert

Have a question? We'll get back to you promptly.